WO1992001002A1 - Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation - Google Patents
Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation Download PDFInfo
- Publication number
- WO1992001002A1 WO1992001002A1 PCT/JP1991/000920 JP9100920W WO9201002A1 WO 1992001002 A1 WO1992001002 A1 WO 1992001002A1 JP 9100920 W JP9100920 W JP 9100920W WO 9201002 A1 WO9201002 A1 WO 9201002A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- necrosis factor
- tumor necrosis
- tnf
- urine
- pro
- Prior art date
Links
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 46
- 230000000694 effects Effects 0.000 title claims abstract description 46
- 102000003390 tumor necrosis factor Human genes 0.000 title claims abstract description 46
- 239000003112 inhibitor Substances 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 150000001413 amino acids Chemical group 0.000 claims abstract description 17
- 239000000126 substance Substances 0.000 claims description 29
- 210000002700 urine Anatomy 0.000 claims description 25
- 230000022534 cell killing Effects 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 4
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 230000000445 cytocidal effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000012264 purified product Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710132632 Protein C4 Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000003323 beak Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101500028161 Homo sapiens Tumor necrosis factor-binding protein 1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102400000089 Tumor necrosis factor-binding protein 1 Human genes 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000019600 saltiness Nutrition 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- PFBLRDXPNUJYJM-UHFFFAOYSA-N tert-butyl 2-methylpropaneperoxoate Chemical compound CC(C)C(=O)OOC(C)(C)C PFBLRDXPNUJYJM-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
Definitions
- Tumor necrosis factor activity inhibitor and method for producing the same
- the present invention relates to a novel substance that suppresses the activity of tumor necrosis factor, and the isolation and purification of the substance.
- Tumor necrosis factor was administered to a CD-1 Swiss mouse with Bacillus Ca1me11e-Gtier II (BCG) bacteria, and two weeks later with bacterial endotoxin (endotoxin) It was discovered as a biologically active substance that appeared in the blood when it was killed, and Carswe! 1 reports [EA Carswe! ! La Pro at! Acad, Sci., USA, 3ot) t U 975:] A bioactive protein whose amino acid sequence was determined in 1985 by Aggarwai et al. [E, B, Aggarwal et al., J. Biol. Diem. 260, 2345 11985). It has been clarified by J.
- TNF TNF-1 fibroblast growth factor
- B. Beutler et al., Science, 229, 869 (1985) Induction of inflammatory response to vascular endothelial cells [J Gamble 'et al., Proc. Xa ⁇ i. A cad. Sc ⁇ ., USA, _82 ⁇ _ 8667 (1985)], ripening [A. D are! Io et al., J. Exp. Med. 163. 1443 (1986)], Interleukin, one of the substances causing inflammation :! ['PP Nawroth et al., J. Exp. Med. 1 _ 1363]
- Noshika has been prepared and is not suitable for administration to the human body Such antibodies are considered to be a major problem.
- immune complex formation is at least a factor that worsens the condition.
- anti-Din'F antibody as a substance having anti-NF activity for such diseases. Therefore, if a human body fluid could contain an anti-Fing agent that could be present naturally, it would be a sufficient, effective and safe treatment for TNF-fighting diseases.
- TNF activity inhibitor also referred to as ⁇ F inhibitor
- Peetre et al. [Eur. J. Haemalc !, ⁇ , 414 (1988), £ 2, -270 (1989)], P. Secger La
- the present inventors have conducted research to search for a novel TNF activity inhibitor, and have reached the present invention.
- An object of the present invention is to provide a novel TNF activity inhibitor, a composition containing the same, and a method for producing the same.
- the present invention encompasses the following inventions. That is, the present invention relates to H) suppressing the cell killing effect of tumor necrosis factor on L929 cells. • 2) SDS-PAGE has a reduced molecular weight of 34
- amino acids from the 1st to the Uth from the ⁇ terminus are substances represented by the following sequence Val-Aia-Phe-Thr-Pro-Tr-Aia-Pro-Ala-Pro-Tr is there
- the substance of the present invention is characterized in that the 11th amino acid from the N-terminus is Va! -AIa-Phe-Tr-Pro-Tyr-Ala-Pro-Ala-? Ro-Thr.
- the substances of the present invention are described in C. Peetre et al. [Eur. J. Haematol. 11, 414 (1988 ⁇ ). However, the difference is that it is 34 K2 1 KDa.
- amino acid sequence from the- ⁇ ⁇ end is completely different from the substance TBPI described in H. Engeimann et al., 7. Bio, Chem. 265, 153L 1990].
- Ding XF is described by Aggarwai et al. Chem. 2345 (1985)] and Shirai et al. [Ature 313. 805: 1985)]. Including natural TNF and recombinant TNF
- L 929 cells are mice
- ATC C strain number is CCL-11, registered under the name L 929 (NCTC clone 929)
- the molecular weight of the substance of the present invention is a substance having a reduced molecular weight in SDS-PAGE of 3'4K / 200 KDa.
- the reduced state in SDS-PAGE refers to the electrical properties of SDS polyacrylamide gel.
- a suitable reducing agent for example, 2-mercaptoethanol, dithiothreitol, etc., at 100 ° C for several minutes to obtain the disulfide in the protein.
- a suitable reducing agent for example, 2-mercaptoethanol, dithiothreitol, etc.
- the substance of the present invention can be obtained by purifying urine.
- it can be obtained by purifying the urine of patients with membranous proliferative glomerulonephritis,
- Membranous proliferative glomerulonephritis clinically involves the deposition of immune complexes in the renal glomeruli, lowering blood complement value, thickening of the glomerular basement membrane, and proliferation of mesangial cells.
- sycaines especially interleukin 6
- the inventor of the present invention determined the F content in the blood of patients with various renal diseases and found that high blood levels of TNF were contained in the blood of patients with membranous proliferative glomerulonephritis. Finally, using the urine of the patient with this disease, we examined the ability to inhibit the activity of DNF and found that it had a high ability to inhibit TNF activity.
- Purification can be performed by combining purification operations such as ion exchange, reversed phase column, and XF immobilization.
- the present invention relates to a method for producing a tumor necrosis factor activity inhibitor
- the urine may be any of primary urine, urine collection, and spot urine.
- urine is collected under aseptic or aseptic conditions as much as possible in order to carry out a bioa / se / se later.
- a protease inhibitor may be added immediately after urine collection, but these additives are not required if urine is immediately transferred to frozen storage. When these additives are added, it is necessary to remove the additives sufficiently by performing appropriate operations, for example, dialysis, ⁇ extracellular filtration, gel filtration, etc.
- Purification may be performed by an ordinary protein purification method. Since a low activity is usually observed in the urine stock solution, it is preferable to first concentrate the urine solution.
- the enrichment method may be based on ordinary biochemical experiment methods such as ultrafiltration, lyophilization, salting out, etc., but in the case of ultrafiltration, salting out, etc., the target substance It is necessary to check in advance the molecular weight and the degree of saltiness that initiates precipitation:
- the substance of the present invention is subjected to separation and purification by adsorbing to a column to which TNF has been applied after the above-mentioned concentration operation, and then specific eluting by elution with a reversed-phase column.
- cell is a substance contained in the fraction in two k Lil concentration cell), column nits Lil concentration used varies depending ⁇ cell Tonito Lil ⁇ gradient, Protein C 4, VYDA and 'Company, 0.46: , 25 cm, and a 150-minute linear gradient of 1 ⁇ to 37% acetonitrile, 2? ⁇ 28%,
- a test sample may be added to a known system for measuring TNF activity.
- Cell killing effect on various tumor cells in vitro known as the Lysie method, cell growth inhibitory effect, fatty acid metabolism of fat cells _ inhibitory effect
- Growth promoting effect of normal fibroblasts and 1 L-6 production inducing effect Neutrophil adhesion promoting effect on endothelial cells, superoxide secretion promoting effect, vascular endothelial cell coagulation activity enhancing effect, osteoclasting effect on bone cells, IL in various cells
- a system for measuring the inducing effect of ⁇ 'mouth mouth staglandins is available. It is particularly preferable to measure the cell killing effect on L929 cells.
- the tumor necrosis factor activity inhibitor of the present invention includes various types of
- the pharmaceutical composition used as a therapeutic agent for the disease of the sword is a pharmaceutical composition containing the substance for suppressing tumor necrosis factor activity of the present invention as an active ingredient, and is other pharmaceutically acceptable. It includes a carrier and is good
- tumors to be used as active ingredients may be used to reduce the antigenicity of the inhibitor of death factor activity or to enhance the physiological activity.
- polyethylene glycol ⁇ PEG polyethylene glycol ⁇ PEG
- dextran it can be modified by a known polymer such as poly-DL-alanine.
- Examples of the form of the pharmaceutical composition include an injectable composition, a suppository and the like, and it is particularly preferable to use the injectable composition as an intravenous composition.
- an injectable composition it is a mixture of a pharmaceutically effective amount of the tumor necrosis factor activity-inhibiting substance of the present invention and a pharmaceutically acceptable carrier, including amino acids, saccharides, and cellulose.
- a pharmaceutically acceptable carrier including amino acids, saccharides, and cellulose.
- activators generally added to injectable compositions, such as derivatives, polyvinylpyrrolidones, and inorganic compounds. Specific examples thereof include glycine and arginine as amino acids. , Alanine and their pharmaceutically acceptable salts, etc.
- the sugars include mannitol, wild boar, il, xyli, oleoresin, milk, and -7'-coose.
- Cellulose derivatives include carboxymethyi / rese / relo-t-tris, methyl 'cell'-mouth, etc .: Polyvinylpyrrolidones have a molecular weight of 10 000 ⁇ 1,000, GOO Bolibulpyrrolidone:
- Examples of the organic acids include ascorbic acid, citric acid, and the salts thereof.
- Examples of the inorganic compound calcium include 10% of hydrogen phosphate, 10% of hydrogen carbonate, and 10% of acetate. There is a room
- Solutions for dissolving these excipients include injection ⁇ distillation, saline for injection or Ringer's solution for injection.
- injections may contain stabilizers, surfactants, tonicity agents, soothing agents, preservatives, buffers, etc. as required.
- Antioxidants such as deuterium pyrosulfite and perscorbic acid: chelating agents such as DTA and thioglycol agents, etc.
- Examples of surfactants include phosphorylates and boroxixylene derivatives
- Non-ionic surfactants such as Examples of the tonicity agent include sodium chloride and the like.
- Soothing agents include benzyl alcohol, xylocaine, procaine and the like.
- Preservatives include parabens, chlorobutanol, benzanolone chloride, and thimerosal.
- buffer examples include sodium salts such as citric acid, acetic acid, and phosphoric acid.
- a novel substance that suppresses the cell killing effect of tumor necrosis factor (TNF) on cells is provided, and a disease considered to be exerted by TNF, for example, endotoxin shock ⁇ ⁇
- TNF tumor necrosis factor
- Many autoimmune diseases such as acute burn, acute liver failure, renal failure and multiple organ failure, rheumatism, SLE, Behcet, V Grade disease at the time of burn, rejection at organ transplantation, coagulation of Kawasaki disease, DIC, etc. It can be used for treating abnormalities, diagnosing abnormalities, etc.
- Urine from a patient with membranous proliferative glomerulitis was concentrated by ultra-filtration with a silicone (Millipore) to a fraction with a molecular weight of 10,000 or more to a volume of 10 ml Tr !? Changed '.' and 'to pH 8.0 (Sample 2)
- the concentrated urine sample was applied to a 4 S DEAE-Sepiiarose column equilibrated with ⁇ OraM Tris pH 8.0 ⁇ 1 : Flow rate 40 ⁇ ir .: After washing with 10m Tris pH 8.0 in zjir, 10mM Tri? -LOOm Elution was carried out with NaC! PH G, and the mixture was collected at 400 m!
- Table 1 shows the cell killing effect of TXF on these L929 cells.
- the peak fraction was further purified by a TNF affinity column and a reversed-phase column, and the X-terminal amino acid sequence was determined.Asp-Ser-Va! -X-Pro-G ! n-Gl-Lys-T rI I e-His-Pro-Gi QX-Asn-Se rI ⁇ e (X is the residue that was not recognized in the 477A type protein sequencer without beak) It was presumed to be a known TNF inhibitor or a TNF receptor fragment, [I. "01 sson et al., Eur. J. Haemat .. 42, 270 (1989); H. Loetscher et al., Ce. j _ ⁇ _ 351 (1990), T.J, Schail, et al., Cell JJ ⁇ 361 (1990;)
- TNF_Inhibtition rate is as follows.
- the final purified product A35G ⁇ was freeze-dried and redissolved in 230 JL St of S. This Sanal 9 ⁇ ! 10 u 2 XSDS—PAGE sample buffer (1 mM Tris — HC] H6.8, 10% Sucrose. 10% SDS, 0.25 mg 'ml bromphenol buffer :), 1 2— After adding mercaptoethanol and heating at 100 ° C for 5 minutes, apply the whole amount to a 10-20 SDS polyacrylamide gradient gel (first character, SDS-PAGPL AT E 10'20>, —) ir. : A fixed Electrophoresis was performed for 120 minutes at a current, and BI-RAD Molecular Weight Standards-Low was used as a molecular weight marker.
- Figure 1 shows the elution profile of the DEAE crude product when applied to a reversed-phase column.
- Figure 2 shows the results of SDS-PAGE under reduced conditions of the final purified product A: ⁇ Sequence list>
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un nouvel inhibiteur de l'activité du facteur de la nécrose tumorale qui inhibe l'effet cytocide d'un facteur de nécrose tumorale et qui a une masse molaire d'environ 34 kDa et une séquence de 11 acides aminés au niveau de la terminaison N de Val-Ala-Phe-Thr-Pro-Tyr-Ala-Pro-Ala-Pro-Thr.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2/181488 | 1990-07-11 | ||
JP18148890 | 1990-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992001002A1 true WO1992001002A1 (fr) | 1992-01-23 |
Family
ID=16101637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000920 WO1992001002A1 (fr) | 1990-07-11 | 1991-07-10 | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1992001002A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271346B1 (en) | 1989-04-21 | 2001-08-07 | Amgen Inc. | TNF Receptors, TNF binding proteins and DNAs coding for them |
US6306820B1 (en) | 1996-12-06 | 2001-10-23 | Amgen Inc. | Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
US6989147B2 (en) | 1996-07-09 | 2006-01-24 | Amgen Inc. | Truncated soluble tumor necrosis factor type-I and type-II receptors |
US7186810B2 (en) | 1998-10-23 | 2007-03-06 | Amgen Inc. | Modified peptides as therapeutic agents |
US7238776B2 (en) | 1989-04-21 | 2007-07-03 | Amgen Inc. | TNF binding proteins |
WO2008054603A2 (fr) | 2006-10-02 | 2008-05-08 | Amgen Inc. | Protéines de liaison à l'antigène du récepteur a de l'il-17 |
EP1992636A2 (fr) | 1999-11-12 | 2008-11-19 | Amgen Inc. | Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc |
EP2002846A2 (fr) | 1996-12-06 | 2008-12-17 | Amgen Inc. | Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1 |
EP2087908A1 (fr) | 2001-06-26 | 2009-08-12 | Amgen, Inc. | Anticorps opgl |
WO2011046958A1 (fr) | 2009-10-12 | 2011-04-21 | Amgen Inc. | Utilisation des proteines se liant a un antigene du recepteur a de l'il-17 |
WO2013016220A1 (fr) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Récepteur a de il-il-17 requis pour biologie il-17c |
WO2015153144A1 (fr) | 2014-03-31 | 2015-10-08 | Kirin-Amgen, Inc. | Procédés de traitement du psoriasis des ongles et du cuir chevelu |
US10072085B2 (en) | 2010-01-15 | 2018-09-11 | Kirin-Amgen, Inc. | Method of treating psoriasis using an IL-17 receptor antibody formulation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02117700A (ja) * | 1988-03-31 | 1990-05-02 | Glaxo Group Ltd | 生物学的に活性な蛋白質 |
WO1990013575A1 (fr) * | 1989-05-09 | 1990-11-15 | Basf Aktiengesellschaft | Nouvelles proteines a effet d'inhibition de tnf et leur preparation |
JPH0330693A (ja) * | 1989-06-29 | 1991-02-08 | Teijin Ltd | 新規生理活性ポリペプチド |
-
1991
- 1991-07-10 WO PCT/JP1991/000920 patent/WO1992001002A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02117700A (ja) * | 1988-03-31 | 1990-05-02 | Glaxo Group Ltd | 生物学的に活性な蛋白質 |
WO1990013575A1 (fr) * | 1989-05-09 | 1990-11-15 | Basf Aktiengesellschaft | Nouvelles proteines a effet d'inhibition de tnf et leur preparation |
JPH0330693A (ja) * | 1989-06-29 | 1991-02-08 | Teijin Ltd | 新規生理活性ポリペプチド |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294352B1 (en) * | 1989-04-21 | 2001-09-25 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US6417158B1 (en) * | 1989-04-21 | 2002-07-09 | Amgen, Inc. | Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF |
US6440693B1 (en) | 1989-04-21 | 2002-08-27 | Rudolf Hauptmann | TNF receptors, TNF binding proteins and DNAS coding for them |
US6271346B1 (en) | 1989-04-21 | 2001-08-07 | Amgen Inc. | TNF Receptors, TNF binding proteins and DNAs coding for them |
US7238776B2 (en) | 1989-04-21 | 2007-07-03 | Amgen Inc. | TNF binding proteins |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
US7282483B2 (en) | 1989-04-21 | 2007-10-16 | Amgen Inc. | Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF |
US6989147B2 (en) | 1996-07-09 | 2006-01-24 | Amgen Inc. | Truncated soluble tumor necrosis factor type-I and type-II receptors |
US7732587B2 (en) | 1996-07-09 | 2010-06-08 | Amgen Inc. | Nucleic acids encoding truncated soluble tumor necrosis factor |
EP2002846A2 (fr) | 1996-12-06 | 2008-12-17 | Amgen Inc. | Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1 |
US6306820B1 (en) | 1996-12-06 | 2001-10-23 | Amgen Inc. | Combination therapy using a TNF binding protein for treating TNF-mediated diseases |
US7186810B2 (en) | 1998-10-23 | 2007-03-06 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1992636A2 (fr) | 1999-11-12 | 2008-11-19 | Amgen Inc. | Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc |
EP2087908A1 (fr) | 2001-06-26 | 2009-08-12 | Amgen, Inc. | Anticorps opgl |
EP3492100A1 (fr) | 2001-06-26 | 2019-06-05 | Amgen Inc. | Anticorps pour opgl |
EP3165539A1 (fr) | 2006-10-02 | 2017-05-10 | Kirin-Amgen, Inc. | Protéines se liant à des antigènes a du récepteur il-17 |
US10208122B2 (en) | 2006-10-02 | 2019-02-19 | Amgen K-A, Inc. | IL-17 receptor A antigen binding proteins |
WO2008054603A2 (fr) | 2006-10-02 | 2008-05-08 | Amgen Inc. | Protéines de liaison à l'antigène du récepteur a de l'il-17 |
US11180564B2 (en) | 2006-10-02 | 2021-11-23 | Amgen K-A, Inc. | IL-17 Receptor A antigen binding proteins |
US11858999B2 (en) | 2006-10-02 | 2024-01-02 | Amgen K-A, Inc. | IL-17 receptor A antigen binding proteins |
WO2011046958A1 (fr) | 2009-10-12 | 2011-04-21 | Amgen Inc. | Utilisation des proteines se liant a un antigene du recepteur a de l'il-17 |
US10072085B2 (en) | 2010-01-15 | 2018-09-11 | Kirin-Amgen, Inc. | Method of treating psoriasis using an IL-17 receptor antibody formulation |
US10808033B2 (en) | 2010-01-15 | 2020-10-20 | Amgen K-A, Inc. | IL-17 receptor antibody formulation |
US11505612B2 (en) | 2010-01-15 | 2022-11-22 | Amgen K-A, Inc. | Method of treating diseases using an IL-17 receptor antibody formulation |
WO2013016220A1 (fr) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Récepteur a de il-il-17 requis pour biologie il-17c |
WO2015153144A1 (fr) | 2014-03-31 | 2015-10-08 | Kirin-Amgen, Inc. | Procédés de traitement du psoriasis des ongles et du cuir chevelu |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bertani et al. | Tumor necrosis factor induces glomerular damage in the rabbit | |
EP0536275B1 (fr) | Inhibiteurs de croissance de tumeurs derives de tissus, procedes de preparation et utilisations desdits inhibiteurs | |
RU2166955C2 (ru) | Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток | |
AU685084B2 (en) | Biologically active TGF-beta1 and TGF-beta2 peptides | |
RU2477727C2 (ru) | ПОЛИПЕПТИД, СЕЛЕКТИВНЫЙ ПО ОТНОШЕНИЮ К ИНТЕГРИНУ αvβ3, СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОДИРУЮЩИЙ ЕГО ПОЛИНУКЛЕОТИД, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ДАННЫЙ ПОЛИПЕПТИД, И СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ | |
AU672606B2 (en) | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases | |
JPH02262593A (ja) | 血管発生病の処置に有用な薬剤及び新規な蛋白質 | |
PT95524B (pt) | Novos factores poliptidicos com actividade estimuladora de celulas indiferenciadas, processo para a sua preparacao e para a preparacao de composicoes farmaceuticas que os contem | |
KR20010006534A (ko) | Ⅱ형 tgf-베타 수용체/면역글로불린 불변 영역 융합 단백질 | |
JP6114186B2 (ja) | 組換えヒトg−csf二量体およびその神経系疾患の治療における用途 | |
WO1992001002A1 (fr) | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation | |
JPH06505983A (ja) | 創傷治癒の促進方法および促進薬 | |
WO2006043972A1 (fr) | Protéine chimère | |
US5451399A (en) | [ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors | |
JP2004002461A (ja) | 表面複合リンホトキシン | |
JP2002512006A (ja) | TNF受容体スーパーファミリーの一員である成熟FLINT(mFLINT)ポリペプチド、または、OPG3の治療上の適用 | |
JPH11507033A (ja) | トロンボポイエチンを精製する方法 | |
US5227302A (en) | DNA encoding platelet derived endothelial cell growth factor (PD-ECGF) | |
US20110212900A1 (en) | Method for prophylactic and/or therapeutic treatment of pain associated with hematopoietic cell transplantation | |
DE68927458T2 (de) | Endothelialzellen-Wachstumsfaktor | |
US20080292628A1 (en) | Chimeric Protein | |
JP2002516339A (ja) | LAIT/sCD14−蛋白質による抗生物質蛋白質およびペプチドの誘導 | |
HU210694B (en) | Method for production of new cell growth regulatory factor | |
CN104356219B (zh) | 一种印鼠客蚤抗心律失常的多肽及其制备方法 | |
US5071956A (en) | Protein with vascular activity derived from monocytes and its analogues, a process for its extraction and their uses for therapeutic purposes and for the preparation of antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB NL SE |
|
ENP | Entry into the national phase |
Ref document number: 2103039 Country of ref document: CA Ref country code: CA Ref document number: 2103039 Kind code of ref document: A Format of ref document f/p: F |